Navigation Links
AMAS Test Measures Lethal Replikin Gene Activity in Lung and Other Cancers
Date:12/6/2007

BOSTON, Dec. 6 /PRNewswire/ -- A gene related to rapid replication and lethality has been found to be present in, and to contain some identical protein sequences in, tobacco mosaic virus and non-small cell lung cancer. The early detection diagnostic test for cancer, the AMAS(R) test, appears to measure this gene's activity.

This is the first of a series of reports on the use of a new methodology to isolate "in silico" and track specific gene activity in normal and several disease states.

This newly identified gene has been named the Replikin Peak Gene (RPG). "Replikins(TM)" are a class of proteins containing high concentrations of amino acids lysine and histidine that have been previously determined to be related to rapid replication and virulence. Using proprietary computer algorithms constructed to identify, count, and track historically this class of proteins, replikins have now been analyzed in 130,488 protein and genome sequences. These include all the accession numbers for common strains of influenza and other lethal virus isolations published between 1917 and 2007 in the PubMed repository. Replikins have been found to be concentrated in specific genomic areas. The area of each genome with the highest concentration of continuous replikin peptides has been isolated in silico and named a Replikin Peak Gene (RPG).

Specific RPGs have been identified and quantified in infectious organisms including viruses, bacteria and trypanosomes (malaria). "Upregulation" of the Replikin Peak Gene is evidenced by an increase in the replikin count in the RPG, that is, in the number of replikins per 100 amino acids. For example, in the case of influenza B, which has not to date been lethal, a low replikin count (less than 4) always occurred in influenza B RPGs between 1940 and 2006, and in quiescent periods of influenza A. In contrast, the replikin counts in lethal influenza A virus RPGs increased to over 20, from as much as one to three years before and during outbreaks. Strain-specific increases in replikin count have appeared in relation to the major influenza pandemics and epidemics, after years of constant low stable counts. Furthermore, a high replikin count of the RPG of an organism has been shown to be associated consistently with a higher percent lethality in the host. The increase in count was frequently detected one year or more before the outbreak was clinically apparent. The ability to identify, count and track replikins in the genomic structure of an emerging organism has been shown to be accurately predictive in advance warning of H5N1 outbreaks, and may have value in the management of influenza epidemics.

The highest replikin count of the RPG found in any organism studied to date is in lethal non-small cell lung cancer. The highest AMAS test results found to date also are in lung cancer. Tobacco mosaic virus has some sequences in its RPG that are identical to those in the RPG in non-small cell carcinoma of the lung. Two structural studies have suggested mobility and inter-organism transfer of replikins associated with lethality.

Replikins have been chemically synthesized and were found experimentally to be immunostimulants, producing strong antibody responses in animals. Synthetic cancer replikins administered to animals produce antibodies that can be measured by the AMAS cancer test. The AMAS test's results are evidently related to the rate of replication in the cancer. In short, the AMAS test measures the activity of the replikins that are unique to cancers, whose concentration is related to lethality.

High replikin counts are present in a wide range of lethal diseases. The structural and functional relationship found between the replikin peak genes of the tobacco mosaic virus and non-small cell lung cancer is one illustration of the relationship between replikin count, rapid replication and virulence. Possible implications of these findings of the same replikin structures and functions in tobacco mosaic virus and lung cancer are under further study.

Detailed data on these studies are the subject of issued and pending published patents and are being presented today at a seminar in New York by Samuel Bogoch, M.D., Ph.D.

FluForecast(R) and ReplikinForecast(TM) are products of Replikins, LLC. The AMAS test is a product of Oncolab, Inc.

Contact:

Samuel Bogoch

646-320-5910

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Oncolab, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Use of certain lipid measures not more effective in predicting coronary heart disease
2. Wild American Shrimp Board Agrees To Implement New Self-Funding Measures
3. People overestimate their self-reported sleep times compared to measures by a sleep test
4. PA Health Department Suggests Measures to Reduce the Spread of MRSA
5. New Measures Improve Heart Care
6. Nano-sized voltmeter measures electric fields deep within cells
7. New Lancet Study: Tobacco Control Measures Are Effective and Affordable Strategies to Reduce Chronic Disease Deaths Globally
8. Jefferson immunology researchers halt lethal rabies infection in brain
9. Customized virus kills brain tumor stem cells that drive lethal cancer
10. Aerosol launches immune response in lungs to wipe out lethal infections
11. Vision restoration therapy shown to improve brain activity in brain injured patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders ... Beyond What You See” body image mannequin art competition. Selected from 15 submissions from ... the winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, a national ... , media relations, social media, content marketing and SEO, is now offering direct, ... an intuitive marketing automation platform. , Rosica will now offer the platform to ...
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to the La Gorce Country Club in Miami Beach to host its Swirl: ...
(Date:2/23/2017)... ... , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be ... Hot,” which will begin airing on February 24, 2017. The show chronicles the weight ... reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC lasted ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... PUNE, India , February 23, 2017 ... "Diagnostic Imaging Market by Product (X-ray Imaging Digital, Analog), ... PET)), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, ... MarketsandMarkets, the report studies the global market over the ... expected to reach ~USD 36.43 Billion by 2021, at ...
(Date:2/23/2017)... , Feb. 23, 2017  As National ... In addition, the Company is helping people live ... its customized prescription savings programs in all 50 ... Prescription Assistance Program  and  California Prescription Assistance Program ... from Columbia University for nutritious eating ...
(Date:2/23/2017)... , Feb. 23, 2017 LG Innotek today announced ... for sterilization applications. As its sterilization performance is 1.5 times higher ... short wavelength ultraviolet rays in the range of 200 -- 280nm, allowing ... of bacteria by destroying their DNA. LG Innotek,s product emits UV ... ...
Breaking Medicine Technology: